Understanding how RAD51 helps maintain DNA stability in cancer cells
Molecular modulator of RAD51 in maintaining genome stability
['FUNDING_R01'] · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · NIH-11071468
This study looks at how a protein called RAD51 helps keep cancer cells healthy by protecting their DNA during stressful times, which could lead to better treatments for patients, especially those with certain genetic changes like BRCA mutations.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSALIND FRANKLIN UNIV OF MEDICINE & SCI (nih funded) |
| Locations | 1 site (NORTH CHICAGO, UNITED STATES) |
| Trial ID | NIH-11071468 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which RAD51, a protein involved in DNA repair, helps maintain genome stability in cancer cells. It focuses on how cells protect stalled DNA replication forks from degradation, which is crucial for cell survival and cancer therapy effectiveness. The study employs advanced techniques like cryo-electron microscopy to visualize the interactions between RAD51 and other proteins involved in this protective process. By uncovering these mechanisms, the research aims to improve cancer treatment strategies, particularly for patients with specific genetic backgrounds like those with BRCA mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancers, particularly those with BRCA mutations or those experiencing resistance to current cancer therapies.
Not a fit: Patients with early-stage cancers or those whose cancer is not related to DNA repair mechanisms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that enhance the stability of DNA in cancer cells, potentially improving treatment outcomes.
How similar studies have performed: Other research has shown promise in understanding DNA repair mechanisms, but this specific approach focusing on RAD51 and calcium signaling is relatively novel.
Where this research is happening
NORTH CHICAGO, UNITED STATES
- ROSALIND FRANKLIN UNIV OF MEDICINE & SCI — NORTH CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHAI, WEIHANG — ROSALIND FRANKLIN UNIV OF MEDICINE & SCI
- Study coordinator: CHAI, WEIHANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, anti-cancer therapy